Allot Launches New Off-network Cybersecurity Solution, Part of its 360-degree Protection Platform
The Allot OffNetSecure solution is an extension of the Allot Secure cybersecurity platform for telecom operators. It provides seamless cyber threat protection for consumer and SMB telecom subscribers when they are not connected to the provider's network, for example, when connected as a guest to a Wi-Fi network. This type of connectivity also gives the service provider an additional branded channel for staying in touch with the subscriber which, until now, has been a 'blind spot' for the provider. As an extension of Allot Secure, OffNetSecure contributes to the 360-degree solution that offers protection against malware, phishing and ransomware attacks.
'Mobile internet access has never been so risky with cyber threats lurking behind any potential tap on the glass. The OffNetSecure solution from Allot completes the circle of protection provided by the unified Allot Secure suite and offers telecom providers a new revenue stream from a service with high adoption rates,' said Angel Fernandez, VP Cybersecurity Products for Allot.
The Allot OffNetSecure solution is implemented on the end customer's Android smartphones and tablets, Apple iPhones and iPads and is activated as a part of the provider's branded customer care or other app that is already running on the customer's device. Unlike endpoint protection clients, Allot OffNetSecure requires no downloading, no installation and no updating by the end customer. Allot OffNetSecure can increase the telecom provider's revenue by enabling them to create premium plans and offer unified provisioning, policies, configurations and reporting with other Allot Secure products.
You can see the OffNetSecure product demo and talk to Allot product experts at the RSA Conference, April 28th through May 1st at booth #5281.
###
Additional Resources:Allot Blog: https://www.allot.com/blogTelco CyberTalk Podcast: https://www.allot.com/resources/podcastsFollow us on Twitter: @allot_ltdFollow us on LinkedIn: https://www.linkedin.com/company/allot-communications
About Allot
Allot Ltd. (NASDAQ: ALLT, TASE: ALLT) is a provider of leading innovative converged cybersecurity solutions and network intelligence for service providers and enterprises worldwide, enhancing value to their customers. Our solutions are deployed globally for network-native cybersecurity services, network and application analytics, traffic control and shaping, and more. Allot's multi-service platforms are deployed by over 500 mobile, fixed and cloud service providers and over 1000 enterprises. Our industry-leading network-native security-as-a-service solution is already used by many millions of subscribers globally.
Allot. See. Control. Secure.
Forward-Looking Statement
This release contains forward-looking statements, which express the current beliefs and expectations of Company management. Such statements involve a number of known and unknown risks and uncertainties that could cause our future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied in such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our accounts receivables, including our ability to collect outstanding accounts and assess their collectability on a quarterly basis; our ability to meet expectations with respect to our financial guidance and outlook; our ability to compete successfully with other companies offering competing technologies; the loss of one or more significant customers; consolidation of, and strategic alliances by, our competitors; government regulation; the timing of completion of key project milestones which impact the timing of our revenue recognition; lower demand for key value-added services; our ability to keep pace with advances in technology and to add new features and value-added services; managing lengthy sales cycles; operational risks associated with large projects; our dependence on fourth party channel partners for a material portion of our revenues; and other factors discussed under the heading "Risk Factors" in the Company's annual report on Form 20-F filed with the Securities and Exchange Commission. Forward-looking statements in this release are made pursuant to the safe harbor provisions contained in the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made only as of the date hereof, and the company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT: Seth Greenberg Allot +972 54 922 2294 sgreenberg@allot.com Ehud Helft Allot Investor Relations +1-212-378-8040 Allot@ekgir.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
34 minutes ago
- Yahoo
Why Iovance Biotherapeutics Stock Was Climbing Today
Key Points Iovance secured conditional approval for its cancer drug in Canada. This is pending the outcome of late-stage clinical trials. 10 stocks we like better than Iovance Biotherapeutics › A piece of good news on the regulatory front and a subsequent bullish analyst update were the factors driving Iovance Biotherapeutics (NASDAQ: IOVA) stock higher on Tuesday. The shares were almost 6% in positive territory in the middle of today's trading session, contrasting very well with the 0.5% slide of the S&P 500 index. Canada's thumbs-up for Amtagvi Just after market close Monday, Iovance announced that its cancer drug Amtagvi had been conditionally approved in Canada for treatment of certain forms of unresectable or metastatic melanoma. This green light from Health Canada, the country's medical regulator, is the biotech's first approval outside its native U.S. Final approval is conditional upon the results of late-stage clinical trials being conducted by the company. It added that it expects to authorize its first specialized treatment center in Canada in order to administer the medicine. It intends to do this at some point in the coming months. Iovance hopes to win approvals for Amtagvi in other jurisdictions with high instances of advanced melanoma specifically, and solid-tumor cancers generally. The drug earned approval from the U.S. Food and Drug Administration (FDA) for a similar indication in February 2024. It was the first cellular therapy to get the FDA's nod. Positive momentum Tuesday morning, H.C. Wainwright analyst Joseph Pantginis reiterated his buy recommendation on Iovance and his $20 per share price target. Not surprisingly, Pantginis' update was focused on the Health Canada move, according to reports. He wrote that it could be something of an inflection point for the healthcare company because Amtagvi will start producing a new revenue stream after final approval and boost the chances of a green light in other jurisdictions. Do the experts think Iovance Biotherapeutics is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Iovance Biotherapeutics make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,076% vs. just 184% for the S&P — that is beating the market by 892.04%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $671,466!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,115,633!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Iovance Biotherapeutics. The Motley Fool has a disclosure policy. Why Iovance Biotherapeutics Stock Was Climbing Today was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Bloomberg
42 minutes ago
- Bloomberg
Fed's Cook Defies Trump Pressure, Possible UK Home Tax, Vape Ban Failings
Your morning briefing, the business news you need in just 15 minutes. On today's podcast: (1) Federal Reserve Governor Lisa Cook signaled her intention to remain at the central bank, defying calls for her resignation by President Donald Trump over allegations of mortgage fraud. (2) Most Federal Reserve officials highlighted inflation risks as outweighing concerns over the labor market at their meeting last month, as tariffs fueled a growing divide within the central bank's rate-setting committee. (3) The NASDAQ declined for the second straight day yesterday, with MAG 7 stocks on their longest losing streak since April. Futures are currently pointing higher for the tech-heavy index, but this week's dip has raised questions if the rally in the sector has gone too far, too fast. (4) UK Chancellor of the Exchequer Rachel Reeves is considering taxing high-value family homes at the point of sale as she looks for ways to plug a multibillion-pound hole in the upcoming budget. (5) European leaders are discussing a security guarantee for Ukraine that would commit Kyiv's allies to decide within 24 hours whether to provide military support to the country if it's again attacked by Russia. (6) A UK ban on disposable vapes is failing to stop users treating refillable devices as if they are still throwaway products, new research shows.
Yahoo
an hour ago
- Yahoo
Cantargia Publishes Half-Year Report 2025
LUND, SE / / August 21, 2025 / Cantargia AB (publ) [Nasdaq Stockholm:CANTA] (Cantargia) today issued the interim report for January to June 2025. "I started my tenure as interim CEO with a strong focus on looking to deliver at least one transformative transaction during 2025. I am delighted for all Cantargia's stakeholders, including our loyal shareholders, our employees and patients in need, that we have been able to deliver on this goal with the Otsuka agreement. Not only does the deal bring significant non-dilutive financial resources but, equally importantly, it provides clear validation of Cantargia's technology and platform. Cantargia is now on a solid footing and our next important task is to prioritize those programs and activities on which we will focus our resources going forward." said Damian Marron, Interim CEO of Cantargia. Significant events in the second quarter Cantargia appointed Morten Lind Jensen as Chief Medical Officer. Treatment resistant atopic dermatitis (AD) was selected as second indication for CAN10's phase 2 program. Pharmacokinetic modelling confirmed the choice of Q4W dosing in phase 2 for CAN10. US FDA awarded nadunolimab Fast Track Designation. Cantargia signed a loan facility of SEK 50 million. Significant events after the end of the period Otsuka Pharmaceuticals acquired CAN10 for an upfront of MUSD 33 plus an additional MUSD 580 in potential milestone payments and up to double digit earn-outs on future sales. The deal is expected to close in Q3 2025. Preliminary results from the TRIFOUR phase 2 study in TNBC did not demonstrate a difference in overall response rate (ORR) between nadunolimab in combination with chemotherapy vs. chemotherapy alone. Cantargia appointed Dr Hilde H. Steineger as new CEO effective from September 1, 2025. Financial information Second quarter 2025 (April 1 - June 30) Net sales: SEK 0.0 M (0.0) Operating loss: SEK -39.5 M (-43.8) Loss after tax: SEK -39.3 M (-43.3) Loss per share, before and after dilution: SEK -0.16 (-0.24) First six months of 2025 (January 1 - June 30) Net sales: SEK 0.0 M (0.0) Operating loss: SEK -84.5 M (-85.5) Loss after tax: SEK -86.2 M (-80.2) Loss per share: before and after dilution, SEK -0.35 (-0.44) Equity/assets ratio: 34 (74) per cent Cash and cash equivalents: SEK 81.9 M (84.7) Short-term investments: SEK 0.0 M (20.0) In conjunction to the report, Cantargia invites investors, analysts, and media to an audiocast with teleconference on August 21, at 3:00 p.m. CEST, where Cantargia's interim CEO Damian Marron, CBO Ton Berkien, and CFO Patrik Renblad, will present Cantargia and comment on the report, followed by a Q&A-session. If you wish to participate via audiocast, please use the link below. Via the web session you will be able to ask written questions. Webcast: . If you wish to participate via teleconference, please register on the link below. After registration you will be provided with phone numbers and a conference ID to access the conference. You can ask questions verbally via the .The webcast will also be available on demand on Cantargia's corporate website: For further information, please contactDamian Marron, Interim CEOTelephone: +46 (0)46-275 62 60E-mail: This information is information that Cantargia is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-08-21 07:00 CEST. About CantargiaCantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP, involved in a number of cancer forms and inflammatory diseases. Cantargia's oncology program, the antibody nadunolimab (CAN04), is being studied clinically, primarily in combination with chemotherapy with a focus on pancreatic cancer, non-small cell lung cancer and triple-negative breast cancer. Positive data for the combinations indicate stronger efficacy than would be expected from chemotherapy alone. Cantargia's second development program, the antibody CAN10, blocks signaling via IL1RAP in a different manner than nadunolimab and addresses treatment of serious autoimmune/inflammatory diseases. Cantargia has entered an agreement with Otsuka Pharmaceuticals on the acquisition of the CAN10 program. Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at . AttachmentsInterim Report January June 2025 SOURCE: Cantargia View the original press release on ACCESS Newswire Sign in to access your portfolio
